Kupararira kweB-cell lymphoma yakakura (DLBCL), NOS, GCB subtype, primary central nervous system lymphoma-01

Muna Zvita 2019, VaWang, mudzidzisi wekuNortheast China, vakatanga kurwadziwa nemusoro. Musi wa19 Zvita, 2019, bvunzo dzekuongorora dzakaratidza zvinotevera: PET-CT yakaratidza mumvuri we density pamwe nekuwedzera kwakanyanya kweFDG metabolism kuruboshwe rwemberi uye nzvimbo yemabvi e corpus callosum (inenge 3.4 * 1.9 cm, SUVmax = 34.4). Biopsy uye immunohistochemistry zvakaratidza diffuse large B-cell lymphoma (DLBCL, NOS, GCB subtype), ine immunophenotype inoratidza Ki67(50%+), CD19(+), CD20(+), PAX5(+), CD79(+), MUM1(+), BCL(+), CD10(-/+), CD2(minor+). Kuongororwa kwe cerebrospinal fluid kwakaratidza 6% mammary lymphoid cells ane morphological variability. Kuongororwa kwacho kwaive primary central nervous system lymphoma (DLBCL, GCB subtype).

Mushure mekutsvagurudza nzira dzekurapa online, VaWang vakadzidza nezve kugona kweBIOOCUS Medical Group immunotherapy uye nekukurumidza vakatsvaga ruzivo rwavo. Mushure mekuongororwa kwakazara kwemuviri uye kuongororwa kwakanyatsoitwa nechikwata chenyanzvi chechipatara, zvakasarudzwa kuti VaWang vatore chikamu mukuyedzwa kwekiriniki kweCART therapy, kunyanya vachishandisa masero eCD19 CART. Vakagamuchira autologous CD19 CAR-T cell infusion musi wa24 Kubvumbi, 2023. Pakazosvika 30 Chikunguru, 2023, vakaongororwa kuti vawana relievement yakakwana (CR) uye kubva ipapo vakadzokera kuhupenyu hwavo hwemazuva ese.